Quarterly Result19 May 2026, 07:31 pm
Mankind Pharma Approves Audited Results for FY26
AI Summary
Mankind Pharma Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board also approved the realignment of security cover for Non-Convertible Debentures post redemption of ₹1,250 Crores. Additionally, Mr. Satish Kumar Sharma was re-appointed as Whole-Time Director for another 5 years, and M/s. M. K. Kulshrestha & Associates were re-appointed as Cost Auditors for FY 2026-27. The board noted the resignation of Mr. Pramod Gokhale, Global Chief Information Officer, effective May 31, 2026, and approved an additional investment of up to ₹500 crores in Mankind Medicare Private Limited.
Key Highlights
- Audited financial results for the quarter and year ended March 31, 2026, approved.
- Security cover realigned for NCDs post ₹1,250 Cr redemption.
- Satish Kumar Sharma re-appointed as Whole-Time Director for 5 years.
- M. K. Kulshrestha & Associates re-appointed as Cost Auditors for FY27.
- Additional investment of up to ₹500 crores approved for Mankind Medicare Private Limited.
Price Impact
More from MANKIND